Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Significant Increase in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS) saw a significant increase in short interest in January. As of January 15th, there was short interest totalling 3,370,000 shares, an increase of 25.7% from the December 31st total of 2,680,000 shares. Based on an average daily volume of 286,800 shares, the short-interest ratio is presently 11.8 days. Currently, 7.4% of the company’s stock are short sold.

Institutional Investors Weigh In On Astria Therapeutics

Several hedge funds have recently bought and sold shares of ATXS. New York State Common Retirement Fund boosted its position in Astria Therapeutics by 67.0% during the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 4,300 shares during the period. Quest Partners LLC lifted its stake in shares of Astria Therapeutics by 180.8% during the 3rd quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock worth $99,000 after buying an additional 5,798 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Astria Therapeutics during the 4th quarter worth about $107,000. PDT Partners LLC bought a new stake in shares of Astria Therapeutics during the 3rd quarter worth about $140,000. Finally, SG Americas Securities LLC acquired a new position in Astria Therapeutics in the 3rd quarter valued at about $155,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Price Performance

ATXS stock traded up $0.37 during trading hours on Friday, reaching $7.86. The stock had a trading volume of 457,247 shares, compared to its average volume of 275,477. The stock has a 50-day simple moving average of $8.93 and a 200 day simple moving average of $10.45. Astria Therapeutics has a fifty-two week low of $7.16 and a fifty-two week high of $16.90. The stock has a market capitalization of $443.54 million, a PE ratio of -3.76 and a beta of 0.70.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ATXS. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Thursday, January 23rd. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a report on Friday. Oppenheimer increased their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Finally, JMP Securities assumed coverage on shares of Astria Therapeutics in a research note on Friday. They issued an “outperform” rating and a $26.00 price target on the stock. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $25.67.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.